CLBIO.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 22:17):

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications...

Stats
今日成交量	3 207.00
平均成交量	10 174.00
市值	221.36M
EPS	SEK0 ( 2024-02-13 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-257.50
ATR14	SEK0.0760 (0.74%)

Corline Biomedical AB 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Corline Biomedical AB 财务报表

Annual	2023
营收:	SEK25.03M
毛利润:	SEK-459 000 (-1.83 %)
EPS:	SEK-0.0842

FY	2023
营收:	SEK25.03M
毛利润:	SEK-459 000 (-1.83 %)
EPS:	SEK-0.0842

FY	2022
营收:	SEK23.55M
毛利润:	SEK22.73M (96.50 %)
EPS:	SEK0.110

FY	2021
营收:	SEK7.06M
毛利润:	SEK9.10M (128.89 %)
EPS:	SEK-0.340

Financial Reports:

No articles found.

Corline Biomedical AB

Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.

实时更新： Corline Biomedical AB [CLBIO.ST]

Upcoming Earnings Alert